U.S. Physical Therapy Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

U.S. Physical Therapy şirketinin kazançları yıllık ortalama -9.9% oranında azalırken, Healthcare sektörünün kazançları yıllık 5.4% oranında artan oldu. Gelirler yıllık ortalama 8% oranında artan oldu. U.S. Physical Therapy şirketinin öz sermaye getirisi 4.7% olup, net marjı 2.2% dir.

Anahtar bilgiler

-9.9%

Kazanç büyüme oranı

-11.8%

EPS büyüme oranı

Healthcare Sektör Büyümesi	8.5%
Gelir büyüme oranı	8.0%
Özkaynak getirisi	4.7%
Net Marj	2.2%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

There May Be Reason For Hope In U.S. Physical Therapy's (NYSE:USPH) Disappointing Earnings

May 21

Recent updates

U.S. Physical Therapy (NYSE:USPH) Might Be Having Difficulty Using Its Capital Effectively

Aug 07

U.S. Physical Therapy (NYSE:USPH) Has A Rock Solid Balance Sheet

Jul 17

U.S. Physical Therapy, Inc.'s (NYSE:USPH) Business Is Trailing The Industry But Its Shares Aren't

Jun 04

There May Be Reason For Hope In U.S. Physical Therapy's (NYSE:USPH) Disappointing Earnings

May 21

U.S. Physical Therapy (NYSE:USPH) Is Due To Pay A Dividend Of $0.44

May 11

Returns On Capital Signal Tricky Times Ahead For U.S. Physical Therapy (NYSE:USPH)

May 05

A Look At The Fair Value Of U.S. Physical Therapy, Inc. (NYSE:USPH)

Apr 21

Is Now The Time To Look At Buying U.S. Physical Therapy, Inc. (NYSE:USPH)?

Apr 07

U.S. Physical Therapy, Inc.'s (NYSE:USPH) Shareholders Might Be Looking For Exit

Mar 04

The Returns On Capital At U.S. Physical Therapy (NYSE:USPH) Don't Inspire Confidence

Dec 23

Why U.S. Physical Therapy, Inc. (NYSE:USPH) Could Be Worth Watching

Dec 07

U.S. Physical Therapy: Positioned For Market Dominance Amidst Attractive Valuations

Oct 13

Are U.S. Physical Therapy, Inc. (NYSE:USPH) Investors Paying Above The Intrinsic Value?

Aug 01

U.S. Physical Therapy: Bolt-On Strategy Scaling Earnings Power (Rating Upgrade)

Jul 19

At US$114, Is U.S. Physical Therapy, Inc. (NYSE:USPH) Worth Looking At Closely?

May 07

U.S. Physical Therapy, Inc.'s (NYSE:USPH) Intrinsic Value Is Potentially 25% Below Its Share Price

Apr 16

U.S. Physical Therapy (NYSE:USPH) Has A Pretty Healthy Balance Sheet

Apr 01

Some Investors May Be Worried About U.S. Physical Therapy's (NYSE:USPH) Returns On Capital

Mar 04

U.S. Physical Therapy beats Q4 top and bottom line estimates; initiates FY23 outlook

Feb 23

U.S. Physical Therapy: Needs To Illustrate Economic Reality Over Accounting Profit

Feb 12

Is Now An Opportune Moment To Examine U.S. Physical Therapy, Inc. (NYSE:USPH)?

Jan 24

We Think U.S. Physical Therapy (NYSE:USPH) Can Stay On Top Of Its Debt

Dec 20

Here's Why We Think U.S. Physical Therapy (NYSE:USPH) Is Well Worth Watching

Dec 05

U.S. Physical Therapy: Not The Most Comfortable Prospect

Nov 09

U.S. Physical Therapy acquires physical therapy practice for $19.3M

Nov 01

U.S. Physical Therapy says Hurricane Ian affected about 50 clinics, ~$395K in lost sales

Oct 17

Gelir ve Gider Dağılımı

U.S. Physical Therapy nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NYSE:USPH Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Sep 24	639	14	57
30 Jun 24	621	16	54
31 Mar 24	606	18	52
31 Dec 23	599	18	52
30 Sep 23	585	24	50
30 Jun 23	575	26	50
31 Mar 23	564	28	48
31 Dec 22	548	29	46
30 Sep 22	536	39	45
30 Jun 22	522	38	46
31 Mar 22	509	37	47
31 Dec 21	490	31	47
30 Sep 21	477	31	47
30 Jun 21	461	30	44
31 Mar 21	418	32	41
31 Dec 20	418	32	42
30 Sep 20	423	30	43
30 Jun 20	431	31	43
31 Mar 20	473	29	45
31 Dec 19	477	31	45
30 Sep 19	472	30	44
30 Jun 19	468	23	44
31 Mar 19	457	18	42
31 Dec 18	449	17	41
30 Sep 18	442	18	41
30 Jun 18	432	22	39
31 Mar 18	421	21	38
31 Dec 17	410	22	36
30 Sep 17	392	20	34
30 Jun 17	377	20	33
31 Mar 17	363	21	32
31 Dec 16	353	21	32
30 Sep 16	348	20	34
30 Jun 16	344	21	33
31 Mar 16	337	21	32
31 Dec 15	327	21	31
30 Sep 15	320	21	30
30 Jun 15	313	20	31
31 Mar 15	308	20	31
31 Dec 14	301	19	30
30 Sep 14	290	19	29
30 Jun 14	278	18	28
31 Mar 14	267	18	27
31 Dec 13	260	18	26

Kaliteli Kazançlar: USPH büyük bir tek seferlik zarar ile $28.5M, 30th September, 2024 tarihine ait son 12 aylık mali sonuçları etkiliyor.

Büyüyen Kar Marjı: USPH 'nin mevcut net kar marjları (2.2%) geçen yılın (4.1%) değerinden daha düşüktür.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: USPH şirketinin kazançları son 5 yılda yılda 9.9% oranında azaldı.

Büyüme Hızlandırma: USPH 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.

Kazançlar vs. Sektör: USPH geçtiğimiz yıl negatif kazanç büyümesine ( -40.6% ) sahipti ve bu da onu Healthcare sektör ortalamasıyla ( 10.1% ) karşılaştırmayı zorlaştırıyordu.

Özkaynak Getirisi

Yüksek ROE: USPH 'nin Özsermaye Getirisi ( 4.7% ) düşük olarak değerlendiriliyor.

U.S. Physical Therapy Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

U.S. Physical Therapy, Inc. to Report Q3, 2024 Results on Nov 05, 2024

U.S. Physical Therapy, Inc. to Report Q2, 2024 Results on Aug 13, 2024

There May Be Reason For Hope In U.S. Physical Therapy's (NYSE:USPH) Disappointing Earnings

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings: EPS misses analyst expectations

U.S. Physical Therapy, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Recent updates

U.S. Physical Therapy, Inc. Declares Quarterly Dividend, Payable on December 6, 2024

U.S. Physical Therapy, Inc. to Report Q3, 2024 Results on Nov 05, 2024

U.S. Physical Therapy, Inc. Declares Quarterly Dividend, Payable on September 13, 2024

U.S. Physical Therapy, Inc. announced delayed 10-Q filing

U.S. Physical Therapy (NYSE:USPH) Might Be Having Difficulty Using Its Capital Effectively

U.S. Physical Therapy, Inc. to Report Q2, 2024 Results on Aug 13, 2024

U.S. Physical Therapy (NYSE:USPH) Has A Rock Solid Balance Sheet

Now 20% undervalued after recent price drop

U.S. Physical Therapy, Inc.'s (NYSE:USPH) Business Is Trailing The Industry But Its Shares Aren't

Chairman & CEO notifies of intention to sell stock

Chairman & CEO recently sold US$212k worth of stock

There May Be Reason For Hope In U.S. Physical Therapy's (NYSE:USPH) Disappointing Earnings

Chief Operating Officer - East recently sold US$261k worth of stock

U.S. Physical Therapy (NYSE:USPH) Is Due To Pay A Dividend Of $0.44

First quarter dividend of US$0.44 announced

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Returns On Capital Signal Tricky Times Ahead For U.S. Physical Therapy (NYSE:USPH)

A Look At The Fair Value Of U.S. Physical Therapy, Inc. (NYSE:USPH)

U.S. Physical Therapy, Inc., Annual General Meeting, May 21, 2024

Is Now The Time To Look At Buying U.S. Physical Therapy, Inc. (NYSE:USPH)?

Executive VP recently sold US$213k worth of stock

Executive VP notifies of intention to sell stock

Price target increased by 9.0% to US$119

Chief Operating Officer - West recently sold US$274k worth of stock

U.S. Physical Therapy, Inc.'s (NYSE:USPH) Shareholders Might Be Looking For Exit

Upcoming dividend of US$0.44 per share

Fourth quarter dividend increased to US$0.44

New minor risk - Profit margin trend

Full year 2023 earnings: EPS misses analyst expectations

U.S. Physical Therapy, Inc. Increases Quarterly Dividend, Payable on April 5, 2024

U.S. Physical Therapy, Inc. to Report Q4, 2023 Results on Feb 28, 2024

U.S. Physical Therapy, Inc. to Report Q4, 2023 Results on Feb 28, 2024

The Returns On Capital At U.S. Physical Therapy (NYSE:USPH) Don't Inspire Confidence

Why U.S. Physical Therapy, Inc. (NYSE:USPH) Could Be Worth Watching

Now 20% undervalued after recent price drop

Price target decreased by 9.6% to US$110

Consensus EPS estimates fall by 10%

U.S. Physical Therapy, Inc. Declares Quarterly Dividend, Payable on December 8, 2023

Price target decreased by 7.9% to US$118

Now 20% undervalued after recent price drop

U.S. Physical Therapy, Inc. to Report Q3, 2023 Results on Nov 07, 2023

U.S. Physical Therapy: Positioned For Market Dominance Amidst Attractive Valuations

Is U.S. Physical Therapy (NYSE:USPH) A Risky Investment?

U.S. Physical Therapy (NYSE:USPH) Could Be Struggling To Allocate Capital

Chief Operating Officer - West recently sold US$452k worth of stock

Should You Think About Buying U.S. Physical Therapy, Inc. (NYSE:USPH) Now?

Chief Operating Officer - West notifies of intention to sell stock

Second quarter 2023 earnings: EPS misses analyst expectations

U.S. Physical Therapy, Inc. Declares Quarterly Dividend, Payable on September 8, 2023

U.S. Physical Therapy, Inc. (NYSE:USPH) acquired a 70% stake in U.S. Physical Therapy, Inc. (NYSE:USPH) for $2.1 million.

Are U.S. Physical Therapy, Inc. (NYSE:USPH) Investors Paying Above The Intrinsic Value?

U.S. Physical Therapy, Inc. to Report Q2, 2023 Results on Aug 08, 2023

U.S. Physical Therapy: Bolt-On Strategy Scaling Earnings Power (Rating Upgrade)

U.S. Physical Therapy, Inc. (NYSE:USPH) acquired 75% interest in Physical therapy practice with four clinics for $3.1 million

U.S. Physical Therapy, Inc. has completed a Follow-on Equity Offering in the amount of $150.00003 million.

Price target increased by 7.9% to US$119

U.S. Physical Therapy, Inc. Elects Nancy Ham to the Board of Directors

Upcoming dividend of US$0.43 per share at 1.6% yield

At US$114, Is U.S. Physical Therapy, Inc. (NYSE:USPH) Worth Looking At Closely?

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

U.S. Physical Therapy Declares Quarterly Dividend, Payable on June 9, 2023

U.S. Physical Therapy, Inc.'s (NYSE:USPH) Intrinsic Value Is Potentially 25% Below Its Share Price

U.S. Physical Therapy (NYSE:USPH) Has A Pretty Healthy Balance Sheet

Independent Director recently sold US$463k worth of stock

Executive VP recently sold US$92k worth of stock

Some Investors May Be Worried About U.S. Physical Therapy's (NYSE:USPH) Returns On Capital

Upcoming dividend of US$0.43 per share at 1.7% yield

Price target increased by 7.5% to US$110

Full year 2022 earnings: EPS misses analyst expectations